Myriad Genetics Inc. (MYGN) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Myriad Genetics Inc. (MYGN) advanced +0.60% to $6.67, trading at 70% of its 52-week range ($2.74 – $8.38). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. I rate BLLN stock as Buy.
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as
The proposed acquisition of the specialty laboratory is the third Labcorp buyout announced in eight days.
Quest Diagnostics (NYSE:DGX) reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as produc
For Myriad Genetics, recent analyst updates around fair value and price targets now cluster mostly in the US$4 to US$8 range, compared with a prior fair value estimate of US$3.91 that has been reset to US$4.49. These shi
Data from ongoing study supports the potential clinical utility of whole-genome sequencing-based Precise MRD™ to identify recurrence risk and detect disease earlier following surgerySALT LAKE CITY, Oct. 22, 2026 (GLOBE N
Buying the Myriad assets will expand Labcorp’s portfolio of specialty tests for women’s health.
Check out the companies making headlines yesterday:
Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index gaining 2.2% and the St
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 22.2% in the pre-market session after the company agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash plus invent
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MYGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MYGN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Myriad Genetics Inc. (MYGN) ranks #667 by composite RQD confidence (39/100, grade D-) and #415 by equity capitalization ($638.0M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with MYGN at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MYGN
ACTIVE
Myriad Genetics Inc. | D- | 39/100 | — | 69.9% | -35.0% | +0.60% | $638.0M | Benchmark Subject |
| ACHV Achieve Life Sciences Inc. | D | 44/100 | — | — | -35.0% | +4.96% | $739.9M | /achv-vs-mygn → |
| NNNN Anbio Biotechnology (Class A) | D | 45/100 | 83.6x | 87.2% | 17.0% | -3.12% | $535.3M | /nnnn-vs-mygn → |
| TKNO Alpha Teknova Inc. | D | 44/100 | — | 33.2% | -21.3% | +2.93% | $499.2M | /tkno-vs-mygn → |
| QDEL QuidelOrtho Corporation | E | 30/100 | — | — | -35.0% | -1.78% | $943.6M | /qdel-vs-mygn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Myriad Genetics Inc. (MYGN) reported GAAP revenue of $824.5M (-1.6% vs. FY2024 revenue of $837.6M , and +9.5% cumulative change since FY2023) , GAAP net income of -$366.0M, operating cash flow of $1.8M, and free cash flow of $1.8M (+120.7% YoY). On the balance sheet, MYGN closed FY2025 with $706.6M in total assets against $119.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $824.5M | -$366.0M | $1.8M | $1.8M | $706.6M | $119.9M |
| FY2024 (FY) | 2024-12-31 | $837.6M | -$127.0M | -$8.7M | -$8.7M | $1.03B | $39.6M |
| FY2023 (FY) | 2023-12-31 | $753.2M | -$263.0M | -$110.9M | -$110.9M | — | — |
As of 2026-11-01, Myriad Genetics Inc. (NASDAQ: MYGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $6.67 (+0.60% 1D, market cap $638.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MYGN ranks #667 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), MYGN carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 69.9%, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $739.9M) and NNNN (Anbio Biotechnology (Class A)) posts a D grade (45/100 RQD, P/E 83.6x, ROIC 17.0%, cap $535.3M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
Per MYGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899923), Myriad Genetics Inc. generated $824.5M in revenue (-1.6% YoY), -$366.0M in net income, and $1.8M in free cash flow against $706.6M in total assets and $119.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MYGN last traded at $6.67 (+0.60% on volume of 1,470,889 shares), positioning the stock +58.43% above its 50-day simple moving average ($4.21) and +44.69% above its 200-day simple moving average ($4.61). Across its 52-week range of $2.74 to $8.38, MYGN sits at the 69.7% percentile with a 14-day RSI of 72.7 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.84 to $7.50).
Why MYGN Stock advanced +0.60% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.